首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1624383

全球人類微生物組市場規模（按產品、應用、地區、範圍和預測）

Global Human Microbiome Market Size By Product (Probiotic, Foods, Medical Foods), By Application (Therapeutics, Diagnostics), By Geographic Scope And Forecast

出版日期: 2024年11月01日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

人類微生物組市場規模及預測

2024 年人類微生物組市場規模價值 6.6836 億美元，預計到 2031 年將達到 28.2857 億美元，2024 年至 2031 年的複合年增長率為 21.80%。人體微生物群是指生活在人體內和體表的所有微生物（細菌、真菌、病毒和其他微生物）。微生物群包含數兆的微生物。主要部位包括腸道、皮膚、口腔、鼻腔及泌尿生殖道。腸道微生物群是研究最廣泛、微生物密度最高的。它在消化、維生素合成和防禦病原體中發揮重要作用。微生物群對於幫助消化、調節免疫系統和預防感染等，保持您的健康至關重要。它也會影響情緒、心理健康和疾病的發展。

每個人都有獨特的微生物群，受遺傳、飲食、環境、年齡和生活方式的影響。它也會因抗生素、疾病和飲食變化等因素而隨著時間而改變。

研究微生物組有助於我們瞭解其在肥胖症、糖尿病、發炎性腸道疾病甚至癌症等疾病中的作用。治療應用包括益生菌、益生元和微生物組移植（例如糞便微生物群移植）。

微生物群與宿主細胞相互作用，有助於代謝功能、免疫反應和體內平衡。菌叢失衡，即微生物群失衡，可導致多種健康問題。

定序技術和生物資訊學的進步極大地提高了我們對人類微生物組的理解。宏基因體學使得無需實驗室培養即可研究微生物群落。

瞭解人類微生物組對於開發新的診斷和治療策略至關重要，凸顯了其在個人化醫療和整體健康中的重要性。

全球人類微生物組市場動態

主要市場推動因素

慢性病盛行率增加：

肥胖症、糖尿病和胃腸道疾病等疾病的增加推動了基於微生物組的治療和診斷的需求。

基因組學和宏基因組學技術的進展：

定序技術和生物資訊學的創新促進了對微生物組的深入分析和理解，從而推動了市場成長。

人們對個人化醫療的興趣日益濃厚：

針對個人微生物群的個人化治療和預防方法變得越來越普遍，推動了市場需求。

政府與私人資助：

政府機構和私人組織對微生物組研究的大量投資和資助正在加速市場的發展。

益生菌和益生元產品的擴展：

消費者對益生菌、益生元和促進健康微生物群的營養補充劑的認識和需求不斷提高，促進了市場擴張。

抗生素抗藥性發生率上升：

抗生素抗藥性的上升加速了對抗生素替代療法的需求，引發了人們對微生物組療法的興趣。

人口老化：

全球人口老化使得人們更容易患上慢性疾病和健康狀況，這推動了對微生物組相關的健康解決方案的需求。

微生物組研究進展：

正在進行的研究揭示了微生物群與各種健康狀況之間的聯繫，擴大了潛在的治療應用，從而推動了市場成長。

主要課題

科學技術的複雜性：

揭示人類微生物組內以及微生物組與宿主之間複雜而動態的相互作用十分複雜。微生物組研究的研究方法標準化仍缺乏。

監管障礙：

針對微生物組相關產品的監管架構仍在發展中。由於該領域的新穎性，獲得新療法和新產品的批准需要時間，並且存在高度的不確定性。

研發成本高：

開發以微生物為基礎的治療和診斷需要在研究、臨床試驗和技術方面進行大量投資。高成本可能會限制中小企業和新創企業的進入。

知識產權問題：

由於生物材料和過程的性質，保護微生物組領域的智慧財產權可能具有課題性。專利情況仍不明朗，為企業帶來不確定性。

有限的臨床證據：

儘管人們的興趣日益濃厚，但證明許多微生物組產品的有效性和安全性的有力臨床證據仍然有限。需要進行更大規模、更長期的臨床試驗來確定可靠性。

微生物組數據的複雜性：

分析和解釋微生物組研究產生的大量數據需要先進的生物資訊工具和專業知識。將微生物組數據與其他健康數據結合也是一個課題。

消費者的認知與接受度：

一般消費者對微生物群及其對健康的影響的理解仍在不斷發展中。教育消費者並獲得他們對微生物相關產品的信任是一項課題。

道德和隱私問題：

微生物組數據的收集和使用引發了道德和隱私問題，特別是在遺傳資訊的儲存和共享方面。確保遵守資料保護法規非常重要。

主要趨勢：

個人化醫療日益受到關註：

根據個人獨特的微生物組特徵擴大個人化治療和診斷。將調整治療方法以提高療效並減少副作用。

微生物組定序技術的進展：

透過次世代定序 (NGS) 和改進的生物資訊學工具進行更深入、更準確的微生物組分析。降低成本並提高定序技術的可近性。

不斷成長的益生菌和益生元市場：

消費者對益生菌、益生元和合生元作為日常膳食補充劑的需求不斷增加。透過配方和遞送機制的創新來提高功效。

數位健康與人工智慧融合：

使用人工智慧和機器學習來分析複雜的微生物組數據。開發用於微生物組監測和個人化推薦的數位健康平台和應用程式。

基於微生物組的治療方法的開發：

增加基於微生物組的一系列疾病治療研究和臨床試驗，包括胃腸道疾病、代謝紊亂和精神健康問題。與微生物組相關的藥物和生物製劑管道正在不斷增長。

微生物組診斷的興起：

開發診斷測試來評估微生物群的健康及其對各種疾病的影響。使用微生物組圖譜來早期發現和監測疾病。

合作與夥伴關係：

製藥和生物技術公司、研究機構和學術中心之間的策略聯盟。合作加速研究、分享數據並開發新產品。

消費者意識與教育：

提高消費者對腸道健康的重要性以及微生物群在整體健康中的作用的認識。進行教育活動和行銷活動來推廣微生物友善產品。

Human Microbiome Market size was valued at USD 668.36 Million in 2024 and is projected to reach USD 2828.57 Million by 2031 , growing at a CAGR of 21.80 % from 2024 to 2031. The human microbiome refers to the collection of all the microorganisms (bacteria, fungi, viruses, and other microbes) that live in and on the human body. The microbiome includes trillions of microorganisms. Major sites include the gut, skin, mouth, nose, and urogenital tract. The gut microbiome is the most extensively studied and has the highest microbial density. It plays a crucial role in digestion, synthesizing vitamins, and protecting against pathogens. The microbiome is essential for maintaining health by aiding in digestion, regulating the immune system, and preventing infections. It also influences mood, mental health, and the development of diseases.

Each individual has a unique microbiome influenced by genetics, diet, environment, age, and lifestyle. It can change over time due to factors such as antibiotics, illness, and diet changes.

Studying the microbiome helps in understanding its role in diseases like obesity, diabetes, inflammatory bowel disease, and even cancer. Therapeutic applications include probiotics, prebiotics, and microbiome transplants (e.g., fecal microbiota transplantation).

The microbiome interacts with the host's cells and contributes to metabolic functions, immune responses, and the maintenance of homeostasis. Dysbiosis, an imbalance in the microbiome, can lead to various health issues.

Advances in sequencing technologies and bioinformatics have significantly enhanced the understanding of the human microbiome. Metagenomics allows the study of microbial communities without needing to culture them in the lab.

Understanding the human microbiome is crucial for developing new diagnostic and therapeutic strategies, highlighting its importance in personalized medicine and overall health.

Global Human Microbiome Market Dynamics

The key market dynamics that are shaping the global human microbiome market include:

Key Market Drivers

Increasing Prevalence of Chronic Diseases:

The rise in conditions such as obesity, diabetes, and gastrointestinal disorders has heightened the demand for microbiome-based therapies and diagnostics.

Advancements in Genomic and Metagenomic Technologies:

Innovations in sequencing technologies and bioinformatics are facilitating detailed analysis and understanding of the microbiome, driving market growth.

Growing Interest in Personalized Medicine:

Personalized approaches to treatment and prevention, tailored to an individual's microbiome, are gaining traction, boosting market demand.

Government and Private Funding:

Significant investments and grants for microbiome research from both governmental bodies and private organizations are accelerating market development.

Expansion of Probiotic and Prebiotic Products:

Increasing consumer awareness and demand for probiotics, prebiotics, and dietary supplements that promote a healthy microbiome are contributing to market expansion.

Rising Incidence of Antibiotic Resistance:

The need for alternative treatments to antibiotics, due to growing antibiotic resistance, is driving interest in microbiome-based therapies.

Aging Population:

An aging global population, more prone to chronic diseases and health conditions, is increasing the need for microbiome-related health solutions.

Advances in Microbiome Research:

Continuous research uncovering the links between microbiomes and various health conditions is expanding potential therapeutic applications, and fueling market growth.

Key Challenges:

Scientific and Technical Complexities:

Understanding the intricate and dynamic interactions within the human microbiome and between the microbiome and host is complex. Standardization of methodologies for microbiome research is still lacking.

Regulatory Hurdles:

Regulatory frameworks specific to microbiome-based products are still evolving. Obtaining approvals for new therapies and products can be time-consuming and uncertain due to the novelty of the field.

High Research and Development Costs:

Developing microbiome-based therapies and diagnostics involves significant investment in research, clinical trials, and technology. High costs can limit the entry of smaller companies and startups.

Intellectual Property Issues:

Protecting intellectual property in the microbiome space is challenging due to the nature of biological materials and processes. Patent landscapes are still unclear, creating uncertainties for companies.

Limited Clinical Evidence:

While there is growing interest, robust clinical evidence demonstrating the efficacy and safety of many microbiome-based products is still limited. More large-scale, long-term clinical trials are needed to establish credibility.

Complexity of Microbiome Data:

Analyzing and interpreting the vast amounts of data generated from microbiome studies requires advanced bioinformatics tools and expertise. Integrating microbiome data with other health data is also challenging.

Consumer Awareness and Acceptance:

Public understanding of the microbiome and its health implications is still developing. Educating consumers and gaining their trust in microbiome-based products can be challenging.

Ethical and Privacy Concerns:

Collecting and using microbiome data raises ethical and privacy issues, especially concerning the storage and sharing of genetic information. Ensuring compliance with data protection regulations is critical.

Key Trends:

Increased Focus on Personalized Medicine:

Growth in personalized treatments and diagnostics based on an individual's unique microbiome profile. Tailoring therapies to enhance efficacy and reduce side effects.

Advancements in Microbiome Sequencing Technologies:

Improvements in next-generation sequencing (NGS) and bioinformatics tools for deeper and more accurate microbiome analysis. Reduced costs and increased accessibility of sequencing technologies.

Expansion of Probiotics and Prebiotics Market:

Rising consumer demand for probiotics, prebiotics, and synbiotics as part of daily dietary supplements. Innovations in formulation and delivery mechanisms to improve effectiveness.

Integration with Digital Health and AI:

Use of artificial intelligence and machine learning to analyze complex microbiome data. Development of digital health platforms and apps for microbiome monitoring and personalized recommendations.

Microbiome-Based Therapeutics Development:

Increased research and clinical trials focused on microbiome-based treatments for various conditions, including gastrointestinal diseases, metabolic disorders, and mental health issues. A growing pipeline of microbiome-related pharmaceuticals and biologics.

Rise in Microbiome Diagnostics:

Development of diagnostic tests to assess the health of the microbiome and its impact on various diseases. Use of microbiome profiles for early disease detection and monitoring.

Collaborations and Partnerships:

Strategic alliances between pharmaceutical companies, biotech firms, research institutions, and academic centers. Collaborative efforts to accelerate research, share data, and develop new products.

Consumer Awareness and Education:

Increasing public awareness of the importance of gut health and the microbiome's role in overall well-being. Educational campaigns and marketing efforts to promote microbiome-friendly products.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Human Microbiome Market Regional Analysis

Here is a more detailed regional analysis of the global human microbiome market:

North America

North America is significantly dominating the human microbiome market and is expected to continue its growth throughout the forecast period, owing to several variables.

North America, particularly the United States, has a strong infrastructure for biomedical research. Leading research institutions and universities are at the forefront of microbiome studies.

Substantial government and private sector funding for microbiome research and development. Venture capital investments in biotech firms specializing in microbiome-based therapies and diagnostics.

Numerous major pharmaceutical and biotechnology companies are headquartered in North America. Collaboration between large firms and startups to innovate and develop new microbiome products.

Early adoption of cutting-edge sequencing technologies and bioinformatics tools. Continuous innovation in metagenomics, data analysis, and computational biology.

Well-developed healthcare systems with the capacity to integrate and utilize new microbiome-based diagnostics and treatments. High demand for personalized medicine and advanced healthcare solutions.

A supportive regulatory environment with agencies like the FDA actively engaging in the development of guidelines for microbiome products. Clearer regulatory pathways encouraging innovation and market entry.

Growing public awareness of the importance of gut health and the human microbiome. Increasing demand for probiotics, prebiotics, and microbiome-related health products.

Asia Pacific

Asia Pacific is anticipated to be the fastest-growing region in the needle-free injection system market investment in healthcare infrastructure and research and development across Asia Pacific countries. Government initiatives to enhance healthcare services and technologies.

Increasing incidence of lifestyle-related diseases such as diabetes, obesity, and gastrointestinal disorders. Demand for innovative treatments and preventive healthcare solutions.

Growth of the biotech and pharmaceutical industries in countries like China, Japan, South Korea, and India. Increase in local and international investments in microbiome research and product development.

A vast and genetically diverse population provides a rich resource for microbiome studies. High potential for personalized medicine and tailored microbiome therapies.

Adoption of cutting-edge technologies in genomic and microbiome research. Establishment of advanced research facilities and collaborations with global institutions.

Growing public awareness of the importance of gut health and the microbiome's role in overall well-being. Increased consumer interest in probiotics, prebiotics, and functional foods.

Implementation of favorable policies and funding schemes to promote biotech and microbiome research. Government support for healthcare innovation and research initiatives.

Rapid economic development and urbanization led to improved healthcare access and spending. Enhanced ability to invest in advanced medical research and technologies.

Global Human Microbiome Market: Segmentation Analysis

The Global Human Microbiome Market is segmented based on Product, Application, And Geography.

Human Microbiome Market, By Product

Probiotic
Foods
Medical Foods
Diagnostic Device
Drugs
Supplements

Based on Product, the market is bifurcated into probiotics, Foods, Medical Foods, Diagnostic Devices, Drugs, and Supplements. The Probiotics segment is showing significant growth in the human microbiome market. Probiotics are a crucial component of the human microbiome market due to their potential to restore gut balance, contribute to overall health, and cater to the growing consumer interest in gut health. As research progresses and innovation continues, we can expect even more diverse and targeted probiotic products to emerge in the market.

Human Microbiome Market, By Application

Therapeutics
Diagnostics

Based on Application, the market is bifurcated into Therapeutics and diagnostics. The therapeutics segment dominates due to the rising development and adoption of microbiome-based therapies. Therapeutics involve microbiome-based treatments for various diseases, while diagnostics focus on identifying and monitoring health conditions through microbiome analysis.

Human Microbiome Market, By Geography

North America
Europe
Asia Pacific
Rest of the world

Based on Regional Analysis, the Global Human Microbiome Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America lead the global human microbiome market, driven by advanced biotechnological and microbiological research infrastructure. The increasing prevalence of lifestyle diseases and autoimmune disorders further boosts market growth in these regions. In North America, the U.S. holds the largest market share, followed by Canada. In Europe, France, Germany, Spain, and the U.K. dominate the market.

Key Players

The "Global Human Microbiome Market" study report will provide valuable insight emphasizing the global market. The major players in the market are
Enterome Bioscience, Seres Therapeutics, Vedanta Biosciences, 4D Pharma, Rebiotix Inc., Second Genome, Synthetic Biologics Inc., Microbiome Therapeutics LLC, uBiome Inc., Ferring Pharmaceuticals, Evelo Biosciences, AOBiome, Osel Inc., Yakult Honsha Co. Ltd.

Our market analysis also entails a section solely dedicated for such major players wherein our analysts provide an insight to the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above-mentioned players globally.

Key Developments

In September 2022, Seres Therapeutics Inc. completed the submission of its Biologics License Application (BLA) to the FDA for SER-109, aiming to prevent recurrent C. difficile infection (CDI). This innovative treatment is poised to enhance current standards of care for CDI.
In September 2022, Ferring Pharmaceuticals received a favorable vote from the FDA's Vaccines and Related Biological Products Advisory Committee for RBX2660. This investigational microbiota-based live biotherapeutic aims to reduce the recurrence of C. difficile infection (CDI) following antibiotic treatment.

1 INTRODUCTION OF GLOBAL HUMAN MICROBIOME MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL HUMAN MICROBIOME MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL HUMAN MICROBIOME MARKET, BY PRODUCT

5.1 Overview
5.2 Probiotic
5.3 Foods
5.4 Medical Foods
5.5 Diagnostic Device
5.6 Drugs
5.7 Supplements

6 GLOBAL HUMAN MICROBIOME MARKET, BY APPLICATION

6.1 Overview
6.2 Therapeutics
6.3 Diagnostics
6.4 Other

7 GLOBAL HUMAN MICROBIOME MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East & Africa

8 GLOBAL HUMAN MICROBIOME MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Share
8.3 Vendor Landscape
8.4 Key Development Strategies

9 COMPANY PROFILES

9.1 Enterome Bioscience
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 E.I. Du Pont De Nemours and Company
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 Merck & Co., Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Metabiomics Corporation
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 Yakult Honsha Co., Ltd.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Microbiome Therapeutics, LLC
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Osel, Inc.
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 Second Genome, Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Vithera Pharmaceuticals
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 Vedanta Biosciences, Inc.
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments